Resources on COVID-19 vaccines development:
- WHO target product profile for COVID-19 vaccine
- Vaccine landscape
- Solidarity vaccine trial
- Access to COVID tools (ACT) Accelerator
- COVAX facility (WHO) Covax explained (GAVI) COPVAX (CEPI)
- WHO guidance on ethnics of vaccine allocation
Working together to deliver vaccine to all countries:
- The Access to Covid-19 Tools (ACT) Accelerator was launched in April 2020 to speed up development and delivery to countries of diagnostics, treatments and vaccines. It includes a health systems connector to support delivery of these resources to countries.
- WHO developed a framework for equitable and affordable access to safe and effective vaccines.
- The COVAX facility is an umbrella mechanism through which demand and resources are pooled to support procurement of, and equitable access to, COVID-19 vaccines.
- The ACT Accelerator aims to deliver two billion vaccine doses for global needs by the end of 2021.
- Vaccine allocation will be driven by public health needs for priority groups, which may represent about 20% of the population, in the first year.
- Countries will be asked to develop vaccination plans.
- WHO recommends front-line personnel (such as health workers) and seniors be the first priority to receive vaccine
WHO Solidarity vaccine trial (Achieving rapid progress towards global objectives) :
- Evaluating several different candidate vaccines:
Increasing the likelihood of finding several effective vaccines
- Expenditiously enrolling people at sites with high rates of COVID-19:
Rapid accumulation of data to support rigorous evaluation
- Eliminating inefficiency of design and conduct of separate trials:
Results within 3-6 months after each vaccine is ready for inclusion
- International collaboration and country commitment:
Fosters international deployment with equity of access
WHO COVID-19 Solidarity vaccine trial :
- On 28 May 2020, WHO announced the launch of a coordinated international, concurrent randomized controlled Phase III trial of different vaccine candidates
- A trial in several sites at once will help speed evaluation and ensure that vaccines will have been tested in different populations
- The trial aims to enroll more than 280.000 from at least 470 different sites in 34 countries
- Local involvement will help to identify trial sites with high COVID-19 transmission to ensure community engagement
COVID-19 vaccine candidates in Phase III trials :
- As of 02 October 2020 there are 42 COVID-19 candidate vaccines in clinical evaluation of which 10 in phase III trials
- There are another 151 candidate vaccines in preclinical evaluation
- Phase III trials usually require 30.000 or more participants
- All top candidate vaccines are for intra-muscular injection
- Most are designed for a two-dose schedule